2026-2034年全球思覺失調症治療藥物市場規模、佔有率、趨勢和成長分析報告

預計到 2034 年，思覺失調症治療市場規模將從 2025 年的 96.9 億美元成長至 148.7 億美元，並預計從 2026 年到 2034 年將以 4.87% 的複合年成長率成長。

世界の精神疾患の有病率増加とメンタルヘルスへの意識提升により、思覺失調症治療薬市場は着実に成長しております。都市區のストレス、薬物乱用、遺伝的素因が主な要因です。政府やヘルスケア機関は早期診断と治療アクセスの重要性を強調しており、ヘルスケア保険適用範囲の拡大やメンタルヘルス支援プログラムの拡充が処方率向上を促進しております。製薬企業は患者の服薬遵守率と治療効果の向上を目指し、長時間作用型注射用抗精神病薬の開発に注力しております。

非典型抗精神病藥物安全性的提高也推動了市場成長。旨在減少體重增加和代謝併發症等副作用的新型藥物製劑備受關注。神經科學研究投入的增加正在加速藥物研發管線的發展。數位健康平台和遠距精神科服務正在擴大患者的就醫途徑。此外，研究機構和製藥公司之間的合作正在增強創新能力並推進臨床試驗。

未來，個人化醫療和基於生物標記的治療方法有望變革治療策略。亞太和拉丁美洲等新興市場由於精神衛生基礎設施的改善，預計將迎來顯著成長。創新藥物候選產品的持續核准將加劇市場競爭。持續進行的提高公眾意識的宣傳活動和消除精神健康污名的舉措將為長期成長提供支持。總體而言，創新和可及性仍將是市場擴張的關鍵決定因素。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球思覺失調症治療市場：依治療領域分類

• 市場分析、洞察與預測
• 第二代
• 第三代
• 其他

第5章 全球思覺失調症治療市場：依治療方法分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第6章 全球思覺失調症治療市場：依分銷管道分類

• 市場分析、洞察と予測
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

第7章 全球思覺失調症治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • H. Lundbeck A/S
  • Otsuka Pharmaceutical Co. Ltd
  • Janssen Pharmaceuticals Inc
  • Eli Lilly And Company
  • AstraZeneca
  • ALLERGAN
  • Vanda Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co. Ltd
  • Alkermes Plc
  • Bristol-Myers Squibb Company

The Schizophrenia Drugs Market size is expected to reach USD 14.87 Billion in 2034 from USD 9.69 Billion (2025) growing at a CAGR of 4.87% during 2026-2034.

The Global Schizophrenia Drugs Market is growing steadily due to increasing mental health awareness and rising prevalence of psychiatric disorders globally. Urban stress, substance abuse, and genetic predisposition are key contributing factors. Governments and healthcare organizations are emphasizing early diagnosis and treatment accessibility. The expansion of healthcare coverage and mental health funding programs is encouraging higher prescription rates. Pharmaceutical companies are focusing on developing long-acting injectable antipsychotics to improve patient adherence and therapeutic effectiveness.

Market growth is also driven by advancements in atypical antipsychotic medications with improved safety profiles. Novel drug formulations targeting reduced side effects such as weight gain and metabolic complications are gaining traction. Increasing investments in neuroscience research are accelerating pipeline developments. Digital health platforms and telepsychiatry services are expanding patient outreach. Additionally, collaborations between research institutions and pharmaceutical firms are strengthening innovation capabilities and clinical trial progress.

In the future, personalized medicine approaches and biomarker-based therapies are expected to transform treatment strategies. Emerging markets in Asia-Pacific and Latin America are anticipated to witness significant growth due to improving psychiatric care infrastructure. Ongoing regulatory approvals for innovative drug candidates will enhance competition. Long-term growth will be supported by continuous awareness campaigns and mental health de-stigmatization initiatives. Overall, innovation and accessibility will remain key determinants of market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutic Class

• Second Generation
• Third Generation
• Others

By Treatment

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• H Lundbeck AS, Otsuka Pharmaceutical Co Ltd, Janssen Pharmaceuticals Inc, Eli Lilly and Company, AstraZeneca, ALLERGAN, Vanda Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Alkermes plc, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY THERAPEUTIC CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutic Class
• 4.2. Second Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Third Generation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY TREATMENT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SCHIZOPHRENIA DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutic Class
  • 7.2.2 By Treatment
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutic Class
  • 7.3.2 By Treatment
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutic Class
  • 7.4.2 By Treatment
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutic Class
  • 7.5.2 By Treatment
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutic Class
  • 7.6.2 By Treatment
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SCHIZOPHRENIA DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 H. Lundbeck A/S
  • 9.2.2 Otsuka Pharmaceutical Co. Ltd
  • 9.2.3 Janssen Pharmaceuticals Inc
  • 9.2.4 Eli Lilly And Company
  • 9.2.5 AstraZeneca
  • 9.2.6 ALLERGAN
  • 9.2.7 Vanda Pharmaceuticals Inc
  • 9.2.8 Sumitomo Dainippon Pharma Co. Ltd
  • 9.2.9 Alkermes Plc
  • 9.2.10 Bristol-Myers Squibb Company